| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2013106646 |
| Title |
Compounds and Methods for The Inhibition of Vcb E3 Ubiquitin Ligase. |
| Abstract |
The present invention relates to novel compounds which find utility as modulators, especially inhibitors of VCB E3 Ubiquitin Ligase and as bioactive agents for use as therapeutics for the stimulation of erythropoiesis in a patient or subject including inducement of EPO production in the patient or subject, for the treatment of chronic anemia and ischemia (limits brain injury during episodes of localized anemia, ischemia and/or stroke and damage to cardiovascular tissue during cardiovascular ischemia), as well as enhancing wound healing processes. Pharmaceutical compositions comprising effective amounts of compounds according to the present invention alone or in combination with an additional erythropoieses stimulating agent such as EPO under the tradename procrit or epogen or darbapoietin alfa under the tradename aranesp. Methods of stimulating erythropoiesis in a subject or patient, including increasing the number of red blood cells and/or hematocrit of the patient, treating anemia, including chronic anemia and anemia associated with chronic kidney disease, dialysis, and cancer chemotherapy, ischemia, stroke and damage to cardiovascular tissue during cardiovascular ischemia as well as enhancing wound healing processes and preventing/reducing scarring secondary to healing represent additional aspects of the present invention. Local enhancement of angiogenesis through induction of VEGF including wound healing and reduction of stent occlusion remain additional aspects of the present invention. |
| Applicant(s) |
Yale University Glaxos Mith Kline Intellectual Property Development Limited Cambridge Enterprise Limited University of Cambridge |
| Representative Drug(s) |
D0Q2SE |
Drug Info
|
IC50 = 4100 nM |
[1] |
| Patent ID |
WO2012163264 |
| Title |
Saucernetin Structurally Simplified Substance and Preparation Method Therefor and Pharmaceutical Composition and Use Thereof. |
| Abstract |
Disclosed a saucernetin structurally simplified substance and the preparation method and pharmaceutical composition and use thereof. In particular, it relates to a compound of general formula (I) show. |
| Applicant(s) |
Institute of Mataria Medica, Chinese Academy of Medical Sciences Chinese Academy of Sciences Institute of Medical Sciences Xie, Ping Xie Ping Chen, Xiaoguang Chen Zhao Jiao, Xiaozhen Focus Liu, Xiaoyu Liu Xu |
| Patent ID |
WO2011128436 |
| Title |
Combination of Hypoxia-Inducible Factor-1 Inhibitors and Toll-Like Receptor-3 Agonists for Treating Solid Tumors. |
| Abstract |
The present invention relates to a combination of a HIF-1 inhibitor and a TLR-3 agonist. The combination is for use as an anti-tumoral agent of a solid tumour, preferably prostate tumor. |
| Applicant(s) |
Universita 'Degli Studi Di Roma "La Sapienza" |
| Patent ID |
WO2010075869 |
| Title |
Toluidine Sulfonamides and Their Use. |
| Abstract |
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)- mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularisation. Also provided is a pharmaceutical composition comprising a compound of the invention and a second therapeutic agent or radiation useful for the treatment or prevention of the mentioned diseases or disorders. In a first aspect the present invention relates to a compound having a structure according to formula (I). |
| Applicant(s) |
European Molecular Biology Laboratory |
